Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | USP1 | O94782 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14961834 | 0.82 | NOTUM (0.68) | NOTUMKEAP1CYP19A1KDM5B | |
| SCHEMBL29800355 | 0.82 | NOTUM (0.53) | NOTUMKEAP1CYP19A1CHEK1 | |
| SCHEMBL20153305 | 0.77 | NOTUM (0.56) | NOTUMKEAP1CYP19A1 | |
| SCHEMBL15362397 | 0.77 | NOTUM (0.65) | NOTUMKEAP1 | |
| SCHEMBL21282981 | 0.77 | KDM4E (0.44) | NOTUMKDM5BUSP1 | |
| SCHEMBL12794021 | 0.75 | NOTUM (1.00) | NOTUMKEAP1CYP19A1KDM5BUSP1 | |
| SCHEMBL14909951 | 0.74 | NOTUM (0.46) | NOTUMKEAP1 | |
| SCHEMBL31157076 | 0.74 | NOTUM (0.46) | NOTUMKEAP1CYP19A1CHEK1 | |
| SCHEMBL27978021 | 0.74 | NOTUM (0.46) | NOTUMKEAP1CYP19A1CHEK1 | |
| SCHEMBL25820283 | 0.73 | RXRA (0.39) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-12 | — | — | US | disclosed |
| US-20210188847-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-10717736-B2 | Pyrrole amides as alpha V integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190256512-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256512-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB1, ITGA1 | NOTUM 3696/4885KEAP1 3759/4885CYP19A1 1825/4885 |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | NOTUM 4507/4885KEAP1 3202/4885CYP19A1 1475/4885 |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | ITGB3, ITGB1, ITGAV | NOTUM 4603/4885KEAP1 3590/4885CYP19A1 1811/4885 |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | NOTUM 4581/4885KEAP1 1772/4885CYP19A1 841/4885 |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | NOTUM 4627/4885KEAP1 1607/4885CYP19A1 1005/4885 |
| US-20210188847-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB3, ITGB1 | NOTUM 4224/4885KEAP1 3859/4885CYP19A1 2220/4885 |
| US-10717736-B2 | Pyrrole amides as alpha V integrin inhibitors | ITGAV, ITGB1, ITGA1 | NOTUM 3696/4885KEAP1 3759/4885CYP19A1 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.